Moderna, Inc. — Director's Dealing 2020

May 14, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2020-05-12

Reporting Person: Zaks Tal Zvi (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-05-12	Common Stock	M	125044	$12.21	Acquired	125044	Direct
2020-05-12	Common Stock	S	300	$67.23	Disposed	124744	Direct
2020-05-12	Common Stock	S	1365	$66.43	Disposed	123379	Direct
2020-05-12	Common Stock	S	25905	$65.46	Disposed	97474	Direct
2020-05-12	Common Stock	S	59913	$64.72	Disposed	37561	Direct
2020-05-12	Common Stock	S	19817	$63.59	Disposed	17744	Direct
2020-05-12	Common Stock	S	17744	$62.65	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-05-12	Stock Option (Right to Buy)	$12.21	M	125044	Disposed	2027-02-23	Common Stock (125044)	Direct

Footnotes

F1: This sale was effected pursuant to a Rule 10b5-1 trading plan.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $67.16 to $67.35. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.13 to $67.11. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.12 to $66.09. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.11 to $65.11. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F6: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.10 to $64.10. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F7: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.09 to $63.05. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F8: 25% of this option vested and became exercisable on February 22, 2018 with the remainder vesting in 12 equal quarterly installments thereafter.